SCHEMBL2648296

SCHEMBL2648296

O=C(O)CCNC(=O)c1ccc(C(=O)C(CC(=O)c2cccc(Br)c2)c2ccc(-c3ccccc3)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
GCGR P47871 9/20 0.47
ADCY6 O43306 2/20 0.47
ADCY3 O60266 2/20 0.47
ADCY9 O60503 2/20 0.47
ADCY5 O95622 2/20 0.47
ADCY8 P40145 2/20 0.47
ADCY7 P51828 2/20 0.47
ADCY2 Q08462 2/20 0.47
ADCY1 Q08828 2/20 0.47
ADCY4 Q8NFM4 2/20 0.47
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2653941 0.90 GCGR (0.50) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL9071429 0.88 GCGR (0.47) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL9071421 0.87 GCGR (0.48) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2656406 0.87 LMNA (0.47) LMNAGCGRNPC1RAB9AL3MBTL1
SCHEMBL2648059 0.86 HDAC3 (0.47) LMNAGCGRNPC1RAB9ASMN1; SMN2
SCHEMBL2648927 0.86 GCGR (0.48) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2652499 0.86 GCGR (0.49) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2655274 0.86 GCGR (0.49) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2660393 0.86 LMNA (0.46) LMNAGCGRADCY6ADCY3ADCY9
SCHEMBL6754632 0.85 GCGR (0.48) GCGRADCY6ADCY3ADCY9ADCY5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1463715-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2004-10-06 EP disclosed
US-6762318-B2 CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION NOVO NORDISK A/S (DK) 2004-07-13 US disclosed
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents PFIZER INC 2003-12-25 US disclosed
WO-2003048109-A1 NOVEL GLUCAGON ANTAGONISTS NOVO NORDISK A/S (DK) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236292-A1 Stimulant releasing glucose from liver cells; antidiabetic agents GPR119, GLP1R, GIPR LMNA 4545/4885GCGR 4/4885ADCY6 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.